FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565309708> ?p ?o ?g. }

• W2565309708 abstract "Abstract Abstract 3440 Nilotinib and dasatinib are second-generation tyrosine kinase inhibitors (TKI) used in patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. There are no randomized clinical trials comparing these drugs in this context. The aim of this study was to compare, retrospectively, the hematological, cytogenetic and molecular response in patients submitted to these second-generation TKI at Hemorio, a public brazilian institution. A total of 114 patients were analyzed, 63 received nilotinib and 51 dasatinib as second-line therapy (55.3% and 44.7%, respectively). The following variables were equally distributed between these two groups (nilotinib vs. dasatinib, respectively): male sex (54% vs. 60.8%, p=0.46), median age at diagnosis (46 vs. 45 years, p=0.76), median time in months using imatinib before the switch (45.2 vs. 44.1, p=0.96), resistance to imatinib (98.4% vs. 98%, p=0.88), presence of the mutation T315I (3.2% vs. 3.9%, p=0.09), patients in chronic phase before the switch (85.7% vs. 86.3%, p=0.93). Use of another second generation TKI, as a third-line therapy, was necessary in 30 out of the 114 patients analyzed (26.1%) because of lack of response. This modification was slightly more frequent in the group initially submitted to nilotinib (31.7% vs. 19.6%, p=0.21). Patients who used a third-line therapy were excluded from response and survival analyzes. Response rates after the second-generation TKI were similar between these two groups (nilotinib vs. dasatinib): complete hematological response until three months (77.8% vs. 87.3%, p=0.24), complete cytogenetic response until six months (21.6% vs. 22.2%, p=0.95) and 12 months (32.4% vs. 33.3%, p=0.94) and major molecular response reached before 12 months (32.7% vs. 21.6%, p=0.25). Two-year overall survival (OS) and progression free-survival (PFS) were similar between these two groups (nilotinib vs. dasatinib, respectively): 92.2% vs. 87.8% (p=0.38) for OS and 87.8% vs. 83.7% (p=0.14) for PFS. Although not statistically significant, two-year OS was inferior in the group of patients who needed a third-line therapy (70.5% vs. 95.6%, p=0.70). Our results suggest that the response and survival rates are similar between nilotinib and dasatinib as second-line therapy for patients with imatinib resistant or intolerant CML. Also, they suggest an inferior prognosis for patients who need a third-line therapy. In this way, the choice between these two TKI for second-line therapy should be guided by the clinical characteristics and the mutation status of the patient. Disclosures: Lobo: NOVARTIS: Research Funding." @default.
• W2565309708 created "2017-01-06" @default.
• W2565309708 creator A5016261784 @default.
• W2565309708 creator A5030013978 @default.
• W2565309708 creator A5046495135 @default.
• W2565309708 creator A5053172567 @default.
• W2565309708 creator A5066092604 @default.
• W2565309708 creator A5069083781 @default.
• W2565309708 creator A5069196354 @default.
• W2565309708 creator A5083886389 @default.
• W2565309708 date "2010-11-19" @default.
• W2565309708 modified "2023-10-17" @default.
• W2565309708 title "Comparasion Between Nilotinib and Dasatinib as Second-Line Therapy for Patients with Chronic Myeloid Leukemia: A Single Center Retrospective Study." @default.
• W2565309708 doi "https://doi.org/10.1182/blood.v116.21.3440.3440" @default.
• W2565309708 hasPublicationYear "2010" @default.
• W2565309708 type Work @default.
• W2565309708 sameAs 2565309708 @default.
• W2565309708 citedByCount "0" @default.
• W2565309708 crossrefType "journal-article" @default.
• W2565309708 hasAuthorship W2565309708A5016261784 @default.
• W2565309708 hasAuthorship W2565309708A5030013978 @default.
• W2565309708 hasAuthorship W2565309708A5046495135 @default.
• W2565309708 hasAuthorship W2565309708A5053172567 @default.
• W2565309708 hasAuthorship W2565309708A5066092604 @default.
• W2565309708 hasAuthorship W2565309708A5069083781 @default.
• W2565309708 hasAuthorship W2565309708A5069196354 @default.
• W2565309708 hasAuthorship W2565309708A5083886389 @default.
• W2565309708 hasConcept C121608353 @default.
• W2565309708 hasConcept C126322002 @default.
• W2565309708 hasConcept C151730666 @default.
• W2565309708 hasConcept C2777413986 @default.
• W2565309708 hasConcept C2777583451 @default.
• W2565309708 hasConcept C2778729363 @default.
• W2565309708 hasConcept C2778820342 @default.
• W2565309708 hasConcept C2779343474 @default.
• W2565309708 hasConcept C2779536868 @default.
• W2565309708 hasConcept C3019892230 @default.
• W2565309708 hasConcept C71924100 @default.
• W2565309708 hasConcept C86803240 @default.
• W2565309708 hasConcept C90924648 @default.
• W2565309708 hasConceptScore W2565309708C121608353 @default.
• W2565309708 hasConceptScore W2565309708C126322002 @default.
• W2565309708 hasConceptScore W2565309708C151730666 @default.
• W2565309708 hasConceptScore W2565309708C2777413986 @default.
• W2565309708 hasConceptScore W2565309708C2777583451 @default.
• W2565309708 hasConceptScore W2565309708C2778729363 @default.
• W2565309708 hasConceptScore W2565309708C2778820342 @default.
• W2565309708 hasConceptScore W2565309708C2779343474 @default.
• W2565309708 hasConceptScore W2565309708C2779536868 @default.
• W2565309708 hasConceptScore W2565309708C3019892230 @default.
• W2565309708 hasConceptScore W2565309708C71924100 @default.
• W2565309708 hasConceptScore W2565309708C86803240 @default.
• W2565309708 hasConceptScore W2565309708C90924648 @default.
• W2565309708 hasLocation W25653097081 @default.
• W2565309708 hasOpenAccess W2565309708 @default.
• W2565309708 hasPrimaryLocation W25653097081 @default.
• W2565309708 hasRelatedWork W103312121 @default.
• W2565309708 hasRelatedWork W2085342571 @default.
• W2565309708 hasRelatedWork W2292060205 @default.
• W2565309708 hasRelatedWork W2549680248 @default.
• W2565309708 hasRelatedWork W2560603071 @default.
• W2565309708 hasRelatedWork W2566062550 @default.
• W2565309708 hasRelatedWork W2566861500 @default.
• W2565309708 hasRelatedWork W2572653796 @default.
• W2565309708 hasRelatedWork W2595454416 @default.
• W2565309708 hasRelatedWork W2596629713 @default.
• W2565309708 hasRelatedWork W2607636687 @default.
• W2565309708 hasRelatedWork W2744568429 @default.
• W2565309708 hasRelatedWork W2810919307 @default.
• W2565309708 hasRelatedWork W2901210431 @default.
• W2565309708 hasRelatedWork W2978622194 @default.
• W2565309708 hasRelatedWork W2979575937 @default.
• W2565309708 hasRelatedWork W2979635970 @default.
• W2565309708 hasRelatedWork W3024857176 @default.
• W2565309708 hasRelatedWork W3025999587 @default.
• W2565309708 hasRelatedWork W591077768 @default.
• W2565309708 isParatext "false" @default.
• W2565309708 isRetracted "false" @default.
• W2565309708 magId "2565309708" @default.
• W2565309708 workType "article" @default.